Targeting neuroinflammation reduces synaptic, neuronal and cognitive loss in 5xFAD Alzheimer mice.

Neuroinflammation is a consistent characteristic of Alzheimer’s disease (AD); however, whether its development drives disease progression or is an epiphenomenon remains unknown (Gyengesy et al., 2020). In this study, we evaluated how treatment with the Immunomodulatory imide drugs (IMiDs) Pomalidomide (Pom) and more potent novel analog 3,6’‐dithioPomalidomide (3,6’‐DP) affects neuronal and synaptic loss as well as cognitive impairment in a 5xFAD transgenic mouse model of AD, by targeting neuroinflammation. These mice are known to develop neuroinflammation consequent to excessive amyloid‐b (Ab) peptide generation.